NCT04557956 2026-04-02Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentNational Cancer Institute (NCI)Phase 1/2 Active not recruiting16 enrolled